Finance

Lists
CTNM:NASDAQ
Contineum Therapeutics Inc
US$ १३.१२
+१.००%
(+०.१३) 1D
US$ १३.१२
०.००% (०.००)
After hours
Closed: अक्टोबर २, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
US$ १३.१५
High
US$ १३.२४
Low
US$ १२.५८
Mkt. cap
४९.३६ करोड
Avg. vol.
५.७२ लाख
Volume
७.९४ लाख
52-wk high
US$ १७.७८
52-wk low
US$ ८.६०
EPS
-US$ १.७४
Shares outstanding
३.३० करोड
No. of employees
५१
Open
US$ १३.१५
High
US$ १३.२४
Low
US$ १२.५८
Mkt. cap
४९.३६ करोड
Avg. vol.
५.७२ लाख
Volume
७.९४ लाख
52-wk high
US$ १७.७८
52-wk low
US$ ८.६०
EPS
-US$ १.७४
Shares outstanding
३.३० करोड
No. of employees
५१
News stories
From web sources and news partners
Moomoo
Moomoo
·
१ घण्टा पहिले
The Next Generational AI Monopoly: Why Rezolve AI ($RZLV) is a Screaming Buy Before a 10x Repricing
Simply Wall Street
Simply Wall Street
·
१ घण्टा पहिले
October 2026 Founder Led Stocks To Watch
marketscreener.com
marketscreener.com
·
४९ मिनेट पहिले
Gold gains as October Fed rate hike prospects fade
MSN
MSN
·
१३ घण्टा पहिले
Spiking bond yields, midterms, earnings to test US stocks' typical fourth-quarter strength
About Contineum Therapeutics Inc
CEO-
Employees५१
Founded२००९
Headquarters-
Sector-
Websitecontineum-tx.com
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current US$ १३.१२
US$ २८.०० (+११३.४१%)
Average
US$ २२.२९ (+६९.८९%)
Lowest
US$ १७.०० (+२९.५७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Matteis
Stifel Nicolaus
Buy
Maintained
US$ २८.००
+११३.४%
09/30/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
US$ २६.००
+९८.२%
09/30/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
US$ २३.००
+७५.३%
09/29/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
US$ १७.००
+२९.६%
09/28/2026
Brian Abrahams
RBC Capital
Buy
Maintained
US$ २१.००
+६०.१%
09/21/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
US$ २२.००
+६७.७%
09/16/2026
Charles Moore
Robert W. Baird
Buy
Maintained
US$ १९.००
+४४.८%
09/15/2026
Last report
२०२६ जुलाई ३०
Fiscal period
Q2 2026
EPS / Est. (USD)
-US$ ०.४० / -US$ ०.४५
+१०.८३%beat
Revenue / Est. (USD)
- / ०.००
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.०५ करोड
१.२० करोड
१.११ करोड
१.२० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४४.३० लाख
५१.१८ लाख
५७.६१ लाख
५४.५४ लाख
Operating expense
१.४९ करोड
१.७१ करोड
१.६९ करोड
१.७४ करोड
Total operating expenses
१.४९ करोड
१.७१ करोड
१.६९ करोड
१.७४ करोड
Operating income
-१.४९ करोड
-१.७१ करोड
-१.६९ करोड
-१.७४ करोड
Other non operating income
१.८३ लाख
-५१.०० हजार
-५७.०० हजार
-६८.०० हजार
EBT including unusual items
-१.२८ करोड
-१.५२ करोड
-१.४५ करोड
-१.५२ करोड
EBT excluding unusual items
-१.२८ करोड
-१.५२ करोड
-१.४५ करोड
-१.५२ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.२८ करोड
-१.५२ करोड
-१.४५ करोड
-१.५२ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.४५
-०.४९
-०.३९
-०.४०
Interest and investment income
१९.५७ लाख
२०.१० लाख
२५.०५ लाख
२३.४२ लाख
Interest expense
-
-
-
-
Net interest expenses
१९.५७ लाख
२०.१० लाख
२५.०५ लाख
२३.४२ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.४९ करोड
-१.७० करोड
-१.६८ करोड
-१.७३ करोड
Gain or loss from assets sale
-
-
२.०० हजार
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू